HDAC Inhibitor L-Carnitine and Proteasome Inhibitor Bortezomib Synergistically Exert Anti-Tumor Activity In Vitro and In Vivo

Combinations of proteasome inhibitors and histone deacetylases (HDAC) inhibitors appear to be the most potent to produce synergistic cytotoxicity in preclinical trials. We have recently confirmed that L-carnitine (LC) is an endogenous HDAC inhibitor. In the current study, the anti-tumor effect of LC...

Descripción completa

Detalles Bibliográficos
Autores principales: Huang, Hongbiao, Liu, Ningning, Yang, Changshan, Liao, Siyan, Guo, Haiping, Zhao, Kai, Li, Xiaofen, Liu, Shouting, Guan, Lixia, Liu, Chunjiao, Xu, Li, Zhang, Change, Song, Wenbin, Li, Bing, Tang, Ping, Dou, Q. Ping, Liu, Jinbao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2012
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527572/
https://www.ncbi.nlm.nih.gov/pubmed/23285100
http://dx.doi.org/10.1371/journal.pone.0052576

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3527572/
https://www.ncbi.nlm.nih.gov/pubmed/23285100
http://dx.doi.org/10.1371/journal.pone.0052576

Ejemplares similares